Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Prostate CancerErectile Dysfunction
Interventions
DRUG

sildenafil citrate and questionaires

"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."

DRUG

placebo tablets and questionaires

"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."

Trial Locations (5)

10021

Memorial Sloan-Kettering Cancer Center, New York

10591

Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

11570

Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan-Kettering Cancer Center at Commack, Commack

07920

Memorial Sloan-Kettering Cancer Center at Basking Ridge, Basking Ridge

All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Beth Israel Medical Center

OTHER

collaborator

St. Luke's-Roosevelt Hospital Center

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00142506 - Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer | Biotech Hunter | Biotech Hunter